2017 AHA / ACC Update on 2014 Valvular Disease Q4

According to the
2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease Failure” p 258

“___________________________  in patients with AF and native aortic valve disease, tricuspid valve disease, or MR and a CHA2DS2-VASc score of 2 or greater”

This is a _______ recommendation.

a) DOAC use is preferable to a VKA ; Class I
b) It is reasonable to use a DOAC as an alternative to a VKA ; Class IIa
c) In select patients, a DOAC may be considered as an alternative to a VKA ; Class IIb
d) A DOAC should not be used as an alternative to a VKA : Class III

DOAC = direct oral anticoagulant
VKA = vitamin K antagonist

click here for answer

(B)

“It is reasonable to use a DOAC as an alternative to a VKA in patients with AF and native aortic valve disease, tricuspid valve disease, or MR and a CHA2DS2-VASc score of 2 or greater (35–38).”

Leave Comment

Your email address will not be published. Required fields are marked *